{"id":"W2122026430","doi":"10.1093/infdis/jis750","title":"Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study","year":2012,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":312,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Dolutegravir; Raltegravir; Regimen; Cohort; Medicine; Viral load; Integrase inhibitor; Elvitegravir; Dosing; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002582891,0.0006242403,0.00140123,0.0002464184,0.0002711701,0.0009687302,0.0003780255,0.0008088351,0.001267545],"category_scores_gemma":[0.002341529,0.0002978014,0.0009961971,0.000270201,0.0004142066,0.0004857495,0.0002919746,0.001127701,0.0004262381],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000558784,"about_ca_system_score_gemma":0.0005588894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009826102,"about_ca_topic_score_gemma":0.001081422,"domain_scores_codex":[0.9992292,0.0003967733,0.00004453257,0.0001035911,0.0001148866,0.0001110319],"domain_scores_gemma":[0.998737,0.0002411663,0.0004003059,0.0001459801,0.0001394441,0.0003361116],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4827934,0.0132271,0.3009402,0.0006822012,0.004337766,0.000396637,0.001203847,0.002140493,0.0396325,0.0001395637,0.002327489,0.152179],"study_design_scores_gemma":[0.08521339,0.2013309,0.6972971,0.00008153891,0.002157954,0.0006881706,0.0002214273,0.00224172,0.005307334,0.0001693815,0.005172986,0.0001180772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980008,0.0008303575,0.00009483139,0.00005334978,0.00001063637,0.0001237802,0.0003328776,0.00001301056,0.0005403343],"genre_scores_gemma":[0.9985104,0.0002453461,0.0001237242,0.00009084077,0.00002199595,0.00006376968,0.0005203432,0.000006465457,0.0004171265],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002582891,"threshold_uncertainty_score":0.01365983,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01656090380541293,"score_gpt":0.27322790795775,"score_spread":0.2566670041523371,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}